Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • New Therapeutic Targets in Cardiovascular Diseases (Upcoming)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI115090

Infantile form of carnitine palmitoyltransferase II deficiency with hepatomuscular symptoms and sudden death. Physiopathological approach to carnitine palmitoyltransferase II deficiencies.

F Demaugre, J P Bonnefont, M Colonna, C Cepanec, J P Leroux, and J M Saudubray

Laboratorie de Biocheimie, INSERM U 75, Faculté de Médecine Necker, Paris, France.

Find articles by Demaugre, F. in: JCI | PubMed | Google Scholar

Laboratorie de Biocheimie, INSERM U 75, Faculté de Médecine Necker, Paris, France.

Find articles by Bonnefont, J. in: JCI | PubMed | Google Scholar

Laboratorie de Biocheimie, INSERM U 75, Faculté de Médecine Necker, Paris, France.

Find articles by Colonna, M. in: JCI | PubMed | Google Scholar

Laboratorie de Biocheimie, INSERM U 75, Faculté de Médecine Necker, Paris, France.

Find articles by Cepanec, C. in: JCI | PubMed | Google Scholar

Laboratorie de Biocheimie, INSERM U 75, Faculté de Médecine Necker, Paris, France.

Find articles by Leroux, J. in: JCI | PubMed | Google Scholar

Laboratorie de Biocheimie, INSERM U 75, Faculté de Médecine Necker, Paris, France.

Find articles by Saudubray, J. in: JCI | PubMed | Google Scholar

Published March 1, 1991 - More info

Published in Volume 87, Issue 3 on March 1, 1991
J Clin Invest. 1991;87(3):859–864. https://doi.org/10.1172/JCI115090.
© 1991 The American Society for Clinical Investigation
Published March 1, 1991 - Version history
View PDF
Abstract

Reported cases of carnitine palmitoyltransferase II (CPT II) deficiency are characterized only by a muscular symptomatology in young adults although the defect is expressed in extra-muscular tissues as well as in skeletal muscle. We describe here a CPT II deficiency associating hypoketotic hypoglycemia, high plasma creatine kinase level, heart beat disorders, and sudden death in a 3-mo-old boy. CPT II defect (-90%) diagnosed in fibroblasts is qualitatively similar to that (-75%) of two "classical" CPT II-deficient patients previously studied: It resulted from a decreased amount of CPT II probably arising from its reduced biosynthesis. Consequences of CPT II deficiency studied in fibroblasts differed in both sets of patients. An impaired oxidation of long-chain fatty acids was found in the proband but not in patients with the "classical" form of the deficiency. The metabolic and clinical consequences of CPT II deficiency might depend, in part, on the magnitude of residual CPT II activity. With 25% residual activity CPT II would become rate limiting in skeletal muscle but not in liver, heart, and fibroblasts. As observed in the patient described herein, CPT II activity ought to be more reduced to induce an impaired oxidation of long-chain fatty acids in these tissues.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 859
page 859
icon of scanned page 860
page 860
icon of scanned page 861
page 861
icon of scanned page 862
page 862
icon of scanned page 863
page 863
icon of scanned page 864
page 864
Version history
  • Version 1 (March 1, 1991): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts